Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Chief Financial Officer | March 02, 2023 | March 06, 2023 |
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | June 24, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 181,978 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Sale · Disposed 6,871 · Balance 181,978 F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
C4 Therapeutics, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2036-06-23 | Direct | 62,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 62,000 · Balance 62,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.82 · Expires 2031-07-08 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). F2: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger").
F2: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:31 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001470831-26-000667 · wk-form4_1782505872.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:12 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 35,500 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001662579-25-000049 · wk-form4_1750450313.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001662579-24-000058 · wk-form4_1719000491.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-06-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:22 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000057 · wk-form4_1686946946.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:47 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,871 | $3.63 | $24,921.12 |
DisclosureSEC source: 0001567619-23-004538 · doc1.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,978 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 21:27 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | PurchaseCommon Stock | 5,667 | $5.60 | $31,735.20 |
DisclosureSEC source: 0001662579-23-000027 · wf-form4_167606442384071.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667 Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 22:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,485 | $5.46 | $13,568.10 |
DisclosureSEC source: 0001567619-23-002174 · doc1.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,849 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,083 | $4.49 | $4,863.75 |
DisclosureSEC source: 0001140361-22-042378 · form4.xml · nonDerivative · entry 2 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,334 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 01:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,172 | $4.49 | $23,222.28 |
DisclosureSEC source: 0001140361-22-042378 · form4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,417 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,940 | $5.04 | $29,907.90 |
DisclosureSEC source: 0001140361-22-030297 · form4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,589 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,853 | $5.63 | $32,952.39 |
DisclosureSEC source: 0001567619-22-012667 · doc1.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,529 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · balance_after: Includes 1,790 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 21:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 966 | $5.32 | $5,136.22 |
DisclosureSEC source: 0001140361-22-019988 · form4.xml · nonDerivative · entry 2 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,592 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 17, 2022 and May 18, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| May 17, 2022 Filed May 19, 2022 21:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,616 | $5.32 | $24,538.66 |
DisclosureSEC source: 0001140361-22-019988 · form4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,558 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 17, 2022 and May 18, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:20 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $22.64 | $0.00 |
DisclosureSEC source: 0001209191-22-019573 · doc4.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2032-03-15 F1 · derivative.exercise_date: 33% of the shares underlying this option shall vest and become exercisable on March 16, 2023, with the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 115,107 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001140361-22-007767 · form4.xml · derivative · entry 4 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,107 Underlying: Common Stock · 115,107 shares Expires 2032-02-28 F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,491 | $9.86 | $14,696.79 |
DisclosureSEC source: 0001140361-22-007767 · form4.xml · nonDerivative · entry 3 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,174 F2 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,272 | $9.86 | $22,392.83 |
DisclosureSEC source: 0001140361-22-007767 · form4.xml · nonDerivative · entry 2 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,665 F2 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 61,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-007767 · form4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,937 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,496 | $14.46 | $36,095.90 |
DisclosureSEC source: 0001567619-22-003052 · doc1.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,702 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $14.46 to $14.75, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. F3 · balance_after: Includes 484 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:13 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 32,000 | Not disclosed Strike: $7.82 | Not disclosed |
DisclosureSEC source: 0001209191-21-065717 · doc4.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2031-07-08 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). F2 · price: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). F2 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price less than $8.50 per share was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive (i) cash in an amount equal to the product of (a) the total number of shares of Issuer common stock subject to such option multiplied by (b) the excess of (x) $8.50 per share over (y) the exercise price payable per share of Issuer common stock under such option, and (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,655 | $17.12 | $62,562.27 |
DisclosureSEC source: 0001567619-21-020778 · doc1.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,714 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 23:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,579 | $12.53 | $44,852.03 |
DisclosureSEC source: 0001567619-21-016148 · doc1.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,369 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 16:06 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 32,000 | $0.00 Strike: $7.82 | $0.00 |
DisclosureSEC source: 0001209191-21-046289 · doc4.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-07-08 F1 · derivative.exercise_date: One-third of the shares subject to the option will vest on July 9, 2022, and the balance of the shares will vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 20:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 5,820 | $14.06 | $81,829.20 |
DisclosureSEC source: 0001567619-21-011898 · doc1.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,948 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · balance_after: Includes 1,802 shares issued on May 28, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,616 | $14.55 | $52,612.80 |
DisclosureSEC source: 0001209191-21-034424 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,966 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,761 | $14.58 | $25,675.38 |
DisclosureSEC source: 0001209191-21-023586 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,582 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.58 to $14.61. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:07 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,461 | $16.74 | $24,457.14 |
DisclosureSEC source: 0001209191-21-017770 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,343 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2021 and March 3, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 68,314 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-21-017033 · doc4.xml · derivative · entry 2 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,314 Underlying: Common Stock · 68,314 shares Expires 2031-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 45,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017033 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,804 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,759 | $20.39 | $35,866.01 |
DisclosureSEC source: 0001209191-21-009055 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,546 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 8, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: Includes 244 shares issued pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,469 | $19.77 | $29,048.01 |
DisclosureSEC source: 0001209191-20-059047 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,061 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 23:38 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,496 | $12.09 | $18,086.64 |
DisclosureSEC source: 0001209191-20-047820 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,530 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2020 and August 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,924 | $10.18 | $39,946.32 |
DisclosureSEC source: 0001209191-20-035488 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,026 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · balance_after: Includes 1,575 shares issued on May 29, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,428 | $11.22 | $16,022.16 |
DisclosureSEC source: 0001209191-20-031005 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,375 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2020 and May 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: Includes 817 shares issued on May 31, 2019 and 656 shares issued on November 29, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 20:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,827 | $9.17 | $16,753.59 |
DisclosureSEC source: 0001209191-20-021699 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,330 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 73,750 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-015362 · doc4.xml · derivative · entry 2 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,750 Underlying: Common Stock · 73,750 shares Expires 2030-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 66,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015362 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,157 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2020, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:47 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,781 | $14.21 | $25,308.01 |
DisclosureSEC source: 0001209191-20-008125 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,282 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021445 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,063 F1 · shares: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,125 | $0.00 Strike: $38.47 | $0.00 |
DisclosureSEC source: 0001209191-19-008568 · doc4.xml · derivative · entry 2 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,125 Underlying: Common Stock · 34,125 shares Expires 2029-02-05 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service.. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:44 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 17,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008568 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,063 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| July 27, 2018 Filed Sep 11, 2018 22:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 2,000 | $36.80 | $73,600.00 |
DisclosureSEC source: 0001209191-18-050564 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $36.40 to $37.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 22:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001209191-18-036488 · doc4.xml · derivative · entry 2 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-06-06 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on June 7, 2019 and the remaining shares vest in equal monthly installments over the following 36 months. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 22:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036488 · doc4.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · shares: 25% of the shares subject to restricted stock units vest on June 7, 2019 and the remaining shares vest in equal annual installments over the following 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.